Table 2:
Demographic, Behavioral, and Clinical Characteristics of Sample Before “Switch” to Integrase Inhibitor-Based Regimen.
| INSTI Overall (n=472) |
EVG (n=132) |
RAL (n=130) |
DTG (n=210) |
|
|---|---|---|---|---|
| Variable | N (%) | n (%) | n (%) | n (%) |
| Age, Median (IQR) | 49 (12) | 48 (12) | 48 (11) | 50 (12) |
| Yeas of Education | ||||
| Less than high school | 154 (33) | 38 (29) | 46 (35) | 70 (33) |
| High school | 148 (31) | 47 (36) | 39 (30) | 62 (30) |
| College or above | 170 (36) | 47 (36) | 45 (35) | 78 (37) |
| Race/ethnicity | ||||
| White, non-Hispanic | 69 (15) | 11 (8) | 24 (18) | 34 (16) |
| White, Hispanic | 25 (5) | 7 (5) | 10 (8) | 8 (4) |
| Black, non-Hispanic | 311 (66) | 97 (73) | 80 (62) | 134 (64) |
| Black, Hispanic | 6 (1) | 1 (1) | 0 (0) | 5 (2) |
| Other, Hispanic | 39 (8) | 7 (5) | 11 (8) | 21 (10) |
| Asian or Pacific Islander | 3 (1) | 2 (2) | 1 (1) | 0 (0) |
| Native American or Alaskan | 4 (1) | 2 (2) | 0 (0) | 2 (1) |
| Other | 15 (3) | 5 (4) | 4 (3) | 6 (3) |
| Average Annual Household Income | ||||
| <$6000 | 48 (10) | 14 (11) | 15 (12) | 19 (9) |
| $6001-12000 | 173 (37) | 48 (36) | 50 (38) | 75 (36) |
| $12001-18000 | 77 (16) | 24 (18) | 21 (16) | 32 (15) |
| $18001-24000 | 47 (10) | 15 (11) | 9 (7) | 23 (11) |
| $24001-30000 | 19 (4) | 6 (5) | 4 (3) | 9 (4) |
| $30000-36000 | 25 (5) | 5 (4) | 6 (5) | 14 (7) |
| $36001-75000 | 54 (11) | 18 (14) | 16 (12) | 20 (10) |
| >$75000 | 29 (6) | 2 (2) | 9 (7) | 18 (9) |
| Currently employed | 165 (35) | 47 (36) | 44 (34) | 74 (35) |
| Married | 146 (31) | 33 (25) | 42 (32) | 71 (34) |
| Currently smoking | 172 (36) | 54 (41) | 53 (41) | 65 (31) |
| Recent Use | ||||
| Alcohol: Drinks/Week, Median (IQR) | 0 (0.9) | 0 (1.7) | 0 (0.2) | 0 (1.0) |
| Marijuana | 85 (18) | 25 (19) | 20 (15) | 40 (19) |
| Crack, cocaine, and/or heroin | 26 (6) | 8 (6) | 7 (5) | 11 (5) |
| Hepatitis C RNA positive | 89 (19) | 14 (11) | 31 (24) | 44 (21) |
| Body Mass Index (kg/m2), median (IQR) | 29.3 (9.5) | 30.9 (9.7) | 28 (9.2) | 30 (10.2) |
| Hypertension | 220 (47) | 68 (52) | 48 (37) | 104 (50) |
| Diabetes | 103 (22) | 27 (20) | 22 (17) | 54 (26) |
| CD4 count, median (IQR) | ||||
| Current | 594 (412) | 630 (376) | 493 (409) | 622 (397) |
| Nadir | 214 (251) | 283 (271) | 409 (145) | 397 (227) |
| HIV RNA (copies/mL), median (IQR) | <20 (69) | <20 (28) | 49 (1562) | <20 (28) |
| Prior AIDS diagnosis | 179 (38) | 27 (20) | 70 (54) | 82 (39) |
| PCL-C Total (Before), mean (sd) | 32.0 (14.3) | 32.9 (14.0) | 30.4 (13.9) | 32.6 (14.8) |
| PCC-C Total (After), mean (sd) | 31.2 (13.9) | 30.1 (13.2) | 31.6 (13.3) | 31.6 (14.8) |
| Presumptive PTSD Dx (Before) | 77 (16) | 19 (14) | 19 (15) | 39 (19) |
| Presumptive PTSD Dx (After) | 75 (16) | 17 (13) | 21 (16) | 37 (18) |
| Monocyte Efficacy Score (Before) mean (sd) | 87.8 (32.4) | 92.0 (31.4) | 86.3 (36.1) | 86.0 (30.3) |
| Monocyte Efficacy Score (After) mean (sd) | 52.8 (24.1) | 63.7 (9.8) | 53.2 (28.4) | 45.8 (25.1) |
| CNS Penetrance Effectiveness Score (Before) mean (sd) | 7.8 (1.6) | 7.4 (1.2) | 8.0 (1.9) | 7.8 (1.5) |
| CNS Penetrance Effectiveness Score (After) mean (sd) | 8.1 (1.8) | 6.3 (0.9) | 8.7 (2.0) | 8.8 (1.2) |
Abbreviations: ART=antiretroviral therapy, INSTI: Integrase Inhibitors, RAL: Raltegravir, EVG: Elvitegravir, DTG: Dolutegravir, PI: Protease Inhibitor, NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitor. Note: ME score is calculated according to table 1 in Shikuma C M, Nakamoto B, Shiramizu B, et al. Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV[J]. Antiviral therapy, 2012, 17(7): 1233.